Inactivated Vaccine Market to See Incredible Growth By 2026: Top Players Pfizer Inc., Merck & Co., Inc., Emergent BioSolutions, Bharat Biotech, and Sanofi, GlaxoSmithKline Plc, Seqirus, Valneva SE

Introduction of new inactivated vaccines after completion of clinical studies are expected to boost growth of the inactivated vaccines market over the forecast period. For instance, in 2017, Merck’s investigational inactivated varicella zoster virus vaccine (V212) showed a decrease in the incidence of herpes zoster case by an estimated 64% in immunocompromised subjects in the first phase 3 trial. Clinical studies also revealed that V212 lessens the incidence of herpes zoster pain by around 69.5%. Moreover, V212 demonstrated 83.7% reduction in the incidence of post herpetic neuralgia.

Download PDF Brochure of This Business Research Report: https://www.worldwidemarketreports.com/sample/196099

Rising prevalence of various viral and bacterial diseases around the globe have increased the demand for inactivated vaccines, which in turn will fuel the market growth. For instance, according to the World Health Organization (WHO) report in 2018, annual epidemics due to influenza were estimated to result in around 3 to 5 million cases of severe illness and around 290,000 to 650,000 deaths. Moreover, WHO 2018 report also showed that around 21 million cases and 222,000 typhoid-related deaths occur annually worldwide.

Inactivated vaccines are not as effective as live-attenuated vaccines. Multiple booster shots and immunologic adjuvants are required to provide an effective immune response against the diseases. Inactivated vaccines are on the U.S. Recommended Childhood Immunization Schedule, which includes the seasonal influenza vaccine and inactivated polio vaccine. Less immunogenicity of older vaccines are propelling demand for newly developed innovative vaccines with better efficacy. Researchers and market players are investing in R&D for the development of safe and effective vaccines, thereby boosting growth of the inactivated vaccines market.

Major players operating in the global inactivated vaccine market include GlaxoSmithKline Plc, Seqirus, Valneva SE, Pfizer Inc., Merck & Co., Inc., Emergent BioSolutions, Bharat Biotech, and Sanofi. Major market players are involved in adopting market strategies such as mergers, acquisitions, partnership, collaborations, and development of new products with leading companies and research institutes, in order to retain dominant position in the market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline Plc’s Shingrix, a zoster vaccine recombinant for the prevention of shingles in adults above the age of 50 years. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.

Request For Customization Of This Business Research Report: https://www.worldwidemarketreports.com/quiry/196099

Inactivated Vaccine Market – Taxonomy

On the basis of vaccine type, the global inactivated vaccine market is segmented into:
Viral Vaccine
Bacterial Vaccine

On the basis of method of inactivation, the global inactivated vaccine market is segmented into:
Solvent Detergent Method
Radiation Method
pH Concentration
Heat Inactivation
Others

On the basis of route of administration, the global inactivated vaccine market is segmented into:
Oral
Subcutaneous
Intravenous
Others

On the basis of geography, the global inactivated vaccine market is segmented into:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Worldwide Market Reports:
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun.

Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1 415 871 0703
Email: sales@worldwidemarketreports.com

This release was published on openPR.